Okogen

About Okogen

Okogen, Inc. is a clinical-stage ophthalmic biotechnology company established in 2015, directing its efforts toward the significant unmet medical need for treatments of acute infectious conjunctivitis, commonly known as pink eye. The company was co-founded by Eric J Daniels and Brian M. Strem, PhD. Dr. Strem, who holds a PhD in Biomedical Engineering from UCLA, brought extensive experience in business development and corporate strategy in ophthalmology from his time at Allergan, Shire, and other biopharmaceutical firms. This background in both the scientific and business facets of ophthalmic drug development was foundational to Okogen's strategic direction.

The company's business model is centered on the clinical development and eventual commercialization of novel ophthalmic therapeutics. Okogen operates in the global ophthalmic pharmaceutical market, which for conjunctivitis is valued at over $4.2 billion annually. Its revenue generation will be contingent upon the successful approval and marketing of its product candidates to healthcare providers who treat eye infections. Initially founded in San Diego, the company relocated its headquarters to Plano, Texas, to be closer to essential resources and infrastructure to support its development and commercialization efforts.

Okogen's primary focus has evolved from a single-asset approach to a broader platform. Its initial lead candidate, OKG-0301, was a broad-spectrum antiviral developed to treat adenoviral conjunctivitis, the most common cause of viral pink eye. This topical formulation of ranpirnase, a targeted ribonuclease (RNase), functions by halting viral replication. Building on this, the company is now advancing a triple-combination eyedrop, OKG-0303, designed as a comprehensive treatment for both bacterial and viral forms of acute infectious conjunctivitis. This fixed-dose combination includes a proprietary antiviral, an ocular decongestant, and an antibacterial agent. In a strategic expansion, Okogen is also developing an AI-driven, image-based evaluation platform to support telehealth applications and improve patient evaluation for this highly contagious condition.

Since its inception, Okogen has secured significant funding to advance its clinical programs. A key milestone was a $10 million Series A funding round in 2018 led by Brandon Capital's Medical Research Commercialisation Fund (MRCF), which supported the initiation of the Phase 2 RUBY clinical trial for OKG-0301 in Australia. More recently, the company closed a Series B financing round, securing funds to complete its Phase 2b clinical program for its lead combination product, with a data readout anticipated in late 2025.